Amrita Krishnan MD FACP of The Judy and Bernard Briskin Center for Multiple Myeloma Research discusses the updates at ASH…
Browsing: Acute Lymphoblastic Leukemia
Ann Eapen, MD, from UC-Irvine Department of Hematology and Oncology is presenting the CLARITY Trial (Bloodwise TAP Study) which looks…
Miguel Risco, MD, from UC-Irvine Department of Hematology and Oncology joins us at MOASCs Spotlight On® Hematology in Huntington Beach…
Deepa Jeyakumar, MD, from UC Irvine Health talks about trying to understand the role of CPX-351 and if can be…
Miguel Risco, MD, from UC-Irvine Department of Hematology and Oncology joins us at MOASCs Spotlight On® Hematology in Huntington Beach…
Deepa Jeyakumar, MD, from UC Irvine Health For Multiple Myeloma Research joins us at MOASCs Spotlight On® Hematology in Huntington…
Amrita Krishnan, MD, from The Judy and Bernard Briskin Center For Multiple Myeloma Research joins us at MOASCs Spotlight On®…
Miguel Risco, MD, from UC-Irvine Department of Hematology and Oncology joins us at MOASCs Spotlight On® Hematology in Huntington Beach…
Deepa Jeyakumar, MD, from UC Irvine Health talks about, Midostaurin, the 1st new and approved AML drug in a long…
Amrita Krishnan, MD, from The Judy and Bernard Briskin Center For Multiple Myeloma Research joins us at MOASCs Spotlight On®…
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center joins us at MOASCs Spotlight On® Hematology in Huntington Beach to…
Deepa Jeyakumar, MD, from UC Irvine Health discusses how IDH2 inhibitor for AML is effective with Relapsed Refractory disease and…
Amrita Krishnan, MD, from The Judy and Bernard Briskin Center For Multiple Myeloma Research joins us at MOASCs Spotlight On®…
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks about the diagnostic criteria for thrombotic thrombocytopenic purpura and how…
Deepa Jeyakumar, MD, from UC Irvine Health talks about 4 new drugs for acute myeloid leukemia including Midostaurin, Gemtuzumab, and…
Amrita Krishnan, MD, from The Judy and Bernard Briskin Center For Multiple Myeloma Research talks about the antibody drug conjugate…
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks about the highlights from Myelodysplastic Syndrome (MDS) and nonmalignant hematology…
Venetoclax is approved for the treatment of relapsed/refractory del17p chronic lymphocytic leukemia (CLL) and has shown activity in patients following…
Ibrutinib is approved for all lines of therapy in chronic lymphocytic leukemia (CLL); however, front-line ibrutinib studies have primarily enrolled…
The rapidly changing landscape of NSCLC treatment has drastically improved outcomes for patients. In this interview, Yvonne Summers, BSc, MB…
Knowledge about the different subtypes of and mutations within NSCLC has increased dramatically in the past 10 years. Here, Yvonne…
Integrated healthcare is vital to provide the optimal care to cancer patients at all stages, from diagnosis to remission and…
Beating cancer takes more than good luck and a good doctor, a high-tech medical center and exotic drugs. It takes…
Only one TKI is approved in a first line setting. Joining us from the 2018 Gastrointestinal Cancers Symposium is Dr.…
Dr. Khaldoun Almhanna, MD, MPH, Department of Gastrointestinal Oncology, Moffitt Cancer Center, Associate Professor of Oncology, University of South Florida…
The AJCC guidelines have incorporated several new features, Kenneth Wang, MD, Director of Advanced Endoscopy Group & Esophageal Neoplasia Clinic,…
The exciting 100,000 Genomes Project has the potential to transform the way patients are cared for. Speaking from the American…
Stivarga (regorafenib) is an effective drug but not one that is easily tolerable. Howard Hochster, MD, talks to us about…
The 100,000 Genomes Project is an exciting NHS programme, which aims to sequence 100,000 genomes from patients with rare diseases…
Bloodwise’s Trials Acceleration Programme (TAP) aims to boost the number and speed of hematological oncology studies in the UK. Here,…
While single agents are able to control relapsed chronic lymphocytic leukemia (CLL) well, they do not provide a cure. In…
The issue of smoking and lung cancer screening poses many questions. Speaking from the British Thoracic Oncology Group (BTOG) Annual…
It widely agreed that we need to identify better methods of detecting lung earlier. There has been great data suggesting…
Reducing the length of diagnostic pathways can increase the number treatment options available and enable better patient experiences. Here, Neal…
Prior to the evaluation of whether lung cancer screening should be adopted, its impact on patient survival must be thoroughly…
The early detection of lung cancer is an exciting field with the potential to greatly improve patient survival. Currently, the…
The National Optimal Lung Cancer Pathway (NOLCP) was a much-discussed topic at the British Thoracic Oncology Group (BTOG) Annual Conference…
Long waits for and between treatments, leading to worse outcomes for patients, are unacceptable. Improved care pathways are required to…
The 2017 National Lung Cancer Audit (NCLA) report launched at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held…
The findings of the National Lung Cancer Audit (NCLA) annual reports provide a means to identify where lung cancer care…
The British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, hosted the launch of the latest National…
As traditional treatments for cancer are being surpassed by immunotherapies, the way in which healthcare providers deliver services must change.…
The landscape of NSCLC treatment is evolving rapidly. In this interview, Yvonne Summers, BSc, MB ChB, MSc, PhD, FRCP from…
The British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK revealed the latest clinical updates on prostate…
Targeted therapy for prostate cancer is a promising field, which is set to grow in the coming year. Here, Robert…
The identification of effective systemic medications for prostate cancer has been relatively recent and this field is now making exciting…
At the 2018 Gastrointestinal Cancers Symposium, David Ilson, MD, PhD, from the Memorial Sloan Kettering Cancer Center talks about a…
The common discussion of where to start a patients dosage of regorafenib. Steven J. Cohen, MD, the Chief of the…
Determining the progression and the responses of Hepatocellular Carcinoma (HCC). Professor Andrew X. Zhu, MD, PhD from Harvard Medical School…
The choice of first line therapy differs on tumor sidedness. Professor Alan P. Venook, MD, joins us from the 2018…